Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Y. Robbins, S. Greene, J. Friedman, P. E. Clavijo, C. Van Waes, K. P. Fabian, M. R. Padget, H. Abdul Sater, J. H. Lee, P. Soon-Shiong, J. Gulley, J. Schlom, J. Hodge, C. Allen
This study shows PD-L1 CAR-engineered NK cells kill cancer cells and inhibit tumor growth by targeting PD-L1, reducing myeloid cells in both preclinical models and patient blood.
bioRxiv · Jan 30, 2020Immunology